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Abstract
Chronic platelet-derived growth factor (PDGF) signal-
ing in glial progenitors leads to the formation of oligo-
dendrogliomas inmice, whereas chronic combinedRas
and Akt signaling leads to astrocytomas. Different
histologies of these tumors imply that the pathways
activated by these two oncogenic stimulations are dif-
ferent, and that the apparent lineage of the tumor cells
may result from specific signaling activity. Therefore,
we have investigated the signaling effects of PDGF in
culture and in gliomas in vivo. In culture, PDGF tran-
siently activates ERK1/2 and Akt, and subsequently
elevates p21 and PCNA expression similar to chronic
PDGF autocrine signaling in cultured astrocytes and
PDGF-induced oligodendrogliomas in vivo. Culture
experiments show that autocrine PDGF stimulation,
and combined active Ras and Akt generate signaling
patterns that are in some ways mutually exclusive. Fur-
thermore, forced Akt activity in the context of chronic
PDGF stimulation results in cells with an astrocytic
differentiation pattern both in culture and in vivo. These
data imply that these two interconvertible signaling
motifs are distinct in mice and lead to gliomas resem-
bling the twomajorgliomahistologies found inhumans.
The ability of signaling activity to convert tumor cells
from one lineage to another presents a mechanism for
the development of tumors apparently comprised of
cells from multiple lineages.
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Introduction
Gliomas are the most common primary central nervous
system (CNS) neoplasms in humans. The two major sub-
groups of gliomas are the astrocytomas and oligodendro-
gliomas, whereas the most malignant glioma, glioblastoma
multiforme (GBM), typically has some astrocytic features.
Patients with oligodendrogliomas generally have a slower
clinical progression and a longer survival period compared
to those with astrocytomas. Based on the differentiation char-
acteristics of these tumors, a few molecular markers are used
to differentially diagnose these two types of gliomas, the most
common of which is glial fibrillary acid protein (GFAP), whose
expression implies astroglial character. Several recent studies
have shown that individual cells within these tumors are
capable of giving rise to cells of multiple lineages [1–3]. These
studies have been interpreted as indicating that cancer stem
cells exist within these tumors.
A wide variety of genetic and epigenetic alterations have
been implicated in human gliomagenesis. These alterations pri-
marily affect two essential cellular processes: cell cycle arrest
and signal transduction. Numerous studies have revealed the
frequent alterations of growth factor signaling in human gliomas,
including epidermal growth factor receptor (EGFR) mutations
and amplifications [4,5], overexpression of platelet-derived
growth factor (PDGF) and/or their receptors [4,6], and over-
expression of fibroblast growth factor (FGF) and/or their recep-
tors [7,8]. The activities of signaling components downstream
of these growth factor receptors have also been documented
in human gliomas, such as the phosphoinositide 3-kinase
(PI3K)/AKT pathway [9], RAS/mitogen-activated protein ki-
nase (MAPK) pathway [10], and phospholipase C (PLC)/
protein kinase C (PKC) pathway [11]. Demonstration that these
alterations in signal transduction are causally related to the for-
mation of gliomas requires modeling of gliomagenesis in exper-
imental animals.
We used somatic cell gene transfer in vivo to demonstrate
that the combined activation of both AKT and RAS pathways
found in human GBMs is sufficient to induce GBM formation
from CNS progenitor cells in mice. In these experiments, active
mutants of AKT and KRAS were transferred specifically to
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nestin-expressing cells postnatally using RCAS vectors [12].
In addition, PDGF and the PDGF receptors are also fre-
quently coexpressed in human glioma cell lines and in
gliomas [13,14], suggesting the possible existence of an
autocrine loop. In order to determine if elevated PDGF
signaling could mimic the induction of GBMs by the com-
bined Ras and Akt signaling, we overexpressed PDGF/B
chain in glial progenitor cells in vivo using the RCAS/tv-a
system [15]. Although constitutive PDGF stimulation was
sufficient to induce gliomas in mice, the resultant tumors
were oligodendrogliomas rather than the astrocytic GBMs
induced with combined activation of AKT and RAS. This
result raises the possibility that constitutive PDGF stimula-
tion might not cause sustained activation of AKT and RAS
pathways in this context.
We demonstrate here that the apparent lineage of these
glioma cells is caused by distinct signaling formats within
these tumors. Chronic PDGF stimulation in cultured glial
progenitor cells actively suppresses the activation of both
AKT and RAS/MAPK pathways. The exclusion of Ras and
Akt activity in chronic PDGF signaling is further illustrated by
forced Ras or Akt activity in PDGF-stimulated cells, leading
to a decrease in PDGFR expression and conversion of
oligodendroglial to astroglial character. These observations
are paralleled in vivo by demonstration that the AKT and
RAS/MAPK pathways have low activity in PDGF-induced
oligodendrogliomas, whereas these same pathways have
elevated activity in astrocytic gliomas driven by the activation
of AKT and RAS. Moreover, forced elevation of the AKT
pathway in oligodendrogliomas converts them to an astro-
cytic morphology. In sum, the existence of two distinct and
interchangeable signaling formats that correspond to the
two main glioma subgroups seen in humans provides one
mechanism for the observation of multiple apparent glial
lineages within a given tumor.
Materials and Methods
RCAS Plasmids
The construction of RCAS-PB and RCAS-PBIG vectors
has been described before [15]. RCAS-lacZ plasmid was
kindly provided by Yi Li (Baylor College of Medicine, Hous-
ton, TX). RCAS-Akt/HA was a gift from Peter Vogt (The
Scripps Research Institute, La Jolla, CA). RCAS-Kras
(G12D) plasmid was kindly provided by Galen Fisher (Medi-
cal University of South Carolina, Charleston, SC).
Establishment and Infection of Primary Brain Cell Cultures
Newborn tv-a transgenic mice were sacrificed and the
whole brains weremechanically dissociated into small pieces
in sterile PBS (Ca2+- and Mg2+-free, pH 7.4) followed by
digestion with 1 ml of 0.25% trypsin–1 mM EDTA in HBSS
(Gibco BRL, Carlsbad, CA) in sterile tubes and incubation in
37jC water bath for 15 minutes with gentle shaking. After
incubation, fresh medium was added to terminate trypsin
digestion and large debris was settled. The single cells were
pelleted, resuspended in DMEM with 10% fetal calf serum
(Gibco BRL), and plated. The supernatants containing var-
ious RCAS virons from DF-1 cell cultures producing various
RCAS viruses were collected in sterile syringes and filtered
through 0.22-mm filters, followed by transfer into 70% to 80%
confluent primary brain cell cultures, which had been plated
and grown in DMEM with 10% fetal calf serum. Infections
were repeated three times with 12-hour intervals.
Immunocytochemistry
The cells were fixed in 20jC methanol and washed
with PBS (pH 7.4) thrice. The dishes were blocked by using
5% normal horse serum diluted in PBS (pH 7.4) for 1 hour
at room temperature with shaking. Monoclonal anti-GFAP
antibody (1:1000; Boehringer Mannheim, Indianapolis, IN)
was diluted in PBS–0.05% Tween 20 with 5% normal
horse serum and incubated with cells at room temperature
for 2 hours or 4jC overnight. Secondary goat antimouse
IgG–fluorescin conjugate (1:200; Vector Laboratories, Bur-
lingame, CA) was diluted in PBS–0.05% Tween 20 with 5%
normal horse serum and incubated with cells at room tem-
perature for 1 hour. The nuclei were counterstainedwithDAPI
(Sigma, St. Louis, MO). The fluorescence was visualized
using a fluorescence microscope (Leica, Wetzlar, Germany)
or a confocal laser microscope (Memorial Sloan-Kettering Can-
cer Center Cytology Core Facility, New York, NY).
Blocking of PDGF Signaling
The cells infected with RCAS-PBIG were cultured in
DMEM supplemented with 10% FCS, penicillin and strepto-
mycin, and L-glutamine. A total of 1  105 cells was plated
and the experiment groups were treated with PTK787 (stock
solution dissolved in DMSO) with the final concentration of
1 mM. The control groups were treated with the same volume
of DMSO.
Western Blot Analysis
Whole cell protein extracts were prepared by using cold
lysis buffer consisting of: M-Per mammalian protein extrac-
tion reagent (Pierce Biochemical, Rockford, IL), 30 mM
sodium fluoride, 1 mM sodium vanadate, and protease inhibi-
tor cocktail tablets (Boehringer Mannheim). Samples were
incubated on ice for 10 minutes and supernatants were
recovered by centrifuging at 14,000 rpm at 4jC for 20
minutes. Protein concentrations were determined by the
BCA method (Pierce Biochemical). Proteins were separated
on SDS-PAGE and transferred to nitrocellulose membrane
(Osmonics, Minnetonka, MN). Blocking reagent was 5%
nonfat dry milk in PBS (pH 7.4). Washing buffer was
PBS (pH 7.4) with 0.1% Tween 20. Polyclonal rabbit anti–
phospho-AKT (Ser437), anti –phospho-ERK1/2 (Ser217/
221), anti –phospho-p38MAPK (Thr180/Tyr182), anti –
phospho-STAT3 (Tyr705), anti – phospho-PKCa/bI I
(Thr638), anti-AKT, anti-ERK1/2 (Cell Signaling Tech-
nology, Beverly, MA), polyclonal rabbit anti-PDGFRa and
anti-PDGFRab (Upstate Biotechnology, Lake Placid,
NY), polyclonal goat antiactin, monoclonal anti–p21/CIP1,
polyclonal rabbit anti–FLK1/VEGFR2 (Santa Cruz Biotech-
nology, Santa Cruz, CA), monoclonal anti-PCNA (Chemicon,
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Temecula, CA), and monoclonal anti-GAPDH were used as
primary antibodies. The respective HRP-conjugated second-
ary antibodies were purchased from Boehringer Mannheim.
Signals were visualized by using ECL chemiluminescence
(Amersham, Indianapolis, IN) or Supersignal chemilumi-
nescence (Pierce Biochemical) and Kodak X-OMAT films.
Activated Ras Pull-Down Assay
The cells infected with RCAS-PBIG, RCAS-Kras (G12V),
or RCAS-lacZ were cultured as above. To block PDGF
signaling, RCAS-PBIG– infected cells were treated with
1 mM PTK787 for 7 days. For the activated Ras pull-down
assay, cells were transferred to reduced serum media (1%
FBS) and whole cell extracts were prepared with ice-cold
lysis buffer containing: 50 mM Tris (pH 7.6), 500 mM NaCl,
0.1% SDS, 0.5% DOC, 1% Triton X-100, 0.5 mM MgCl2,
30 mM NaF, 1 mM Na3VO4, 0.5 mM PMSF, and protease
inhibitor cocktail tablets (Boehringer Mannheim). Samples
were incubated on ice for 30 minutes and supernatants
were collected following centrifugation at 55,000 rpm for
15 minutes at 4jC. Protein concentration was determined
using the Bio-Rad Protein Assay reagent (Bio-Rad, Hercu-
les, CA). One milligram of total protein was then used for
activated Ras pull-down with 10 mg of glutathione-conjugated
Raf-1 GST-RBD beads (Upstate Biotechnology). Samples
were incubated for 45 minutes at 4jC with agitation. Beads
were then washed three times with wash buffer (50 mM
Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5 mM MgCl2,
30 mM NaF, 1 mM Na3VO4, 0.5 mM PMSF, and protease
inhibitor cocktail tablets) and analyzed by Western Blot on
SDS-PAGE as described above. Monoclonal mouse anti-
Kras antibody was from Santa Cruz Biotechnology.
Infection of tv-a Transgenic Mice
DF-1 cells producing various RCAS virons were tryp-
sinized and pelleted by centrifugation; the pellets were resus-
pended in approximately 50 ml of DMEM medium and placed
on ice before injection. Using a 10-ml gas-tight Hamilton
syringe, a single intracranial injection of 1 ml of cell suspension
(about 105 cells) was made in the right frontal region of
newborn mice, with the tip of the needle just touching the
skull base.
Brain Sectioning, Hematoxylin and Eosin (H&E)
Staining, and Immunohistochemistry
Mice were sacrificed before (due to early symptoms) or at
12 weeks of age, and the whole brains were fixed in 4%
formaldehyde in PBS for at least 36 hours with shaking. Five
sections of each brain were cut and embedded in paraffin;
5-mm sections were cut with a Leica microtome. The sections
were stained with H&E. Immunostaining of paraffin sections
was performed using ABC kits (Vector Laboratories). Briefly,
deparaffinized slides were first treated with antigen unmask-
ing reagent (Vector Laboratories) with heating in a steamer
for 30 minutes, followed by immersion in 10% hydrogen
peroxide in methanol for 20 minutes to inactivate the endo-
genous peroxidases. Then the sections were blocked with
1.5% normal horse serum in PBS (pH 7.4) for 1 hour at room
temperature. Monoclonal anti-GFAP (1:1000; Boehringer
Mannheim) and polyclonal rabbit anti-HA (1:200; Santa Cruz
Biotechnology) were diluted in PBS–0.05% Tween 20 with
5% normal horse serum (Vector Laboratories) and incubated
with sections at 37jC for 1 hour; polyclonal rabbit anti–
phospho-AKT (Ser473) and anti –pERK1/2(Ser217/221)
(Cell Signaling Technology) were diluted at 1:100 in PBS–
0.05% Tween 20 with 5% normal horse serum (Vector Lab-
oratories) and incubated with sections at 4jC overnight;
mousemonoclonal anti-Olig2 antibody (a gift of John Alberta,
Dana-Farber Cancer Institute, Boston, MA) was diluted at
1:200 in PBS–0.05% Tween 20 with 5% normal horse serum
(Vector Laboratories) and incubated with sections at 4jC
overnight. After washing with PBS–0.05% Tween 20, appro-
priate biotinylated secondary antibodies (Vector Laborato-
ries) diluted in the same antibody dilution buffer were
incubated with sections at 37jC for 60 minutes. Then, after
washing, avidin-conjugated peroxidase (Vector Laborato-
ries) diluted in PBS containing 1.5% normal horse serum
was incubated with sections for 60 minutes at room tempera-
ture. Finally, after exclusive PBS-T washing, DAB substrate
(Vector Laboratories) was added to develop the color.
After terminating the staining reaction, the sections were
counterstained with hematoxylin and mounted. The negative
controls were included with the same procedure, except
replacing primary antibodies with antibody dilution buffer.
Results
Absence of Activated AKT and RAS Pathways in
PDGF-Induced Oligodendrogliomas
In order to determine the status of AKT and RAS/MAPK
pathways in PDGF-induced oligodendrogliomas in situ, we
performed immunohistochemical staining of tumor sections
with antibodies that specifically recognize the phospho-
rylated form of AKT (Ser473) and ERK1/2 (Thr202/Tyr204).
In both cases, phosphorylation represents the active state of
each enzyme [16,17]. Immunostaining for these substrates
was readily visible in the neoplastic cells of AKT+RAS–
induced glioblastomas, particularly within the invading tumor
edges (Figure 1, a–d ). by contrast, staining for both pAKT
and pERK1/2 in the neoplastic cells of PDGF-induced oligo-
dendrogliomas was below detection, even after long expo-
sure to peroxidase substrate. More convincingly, in regions
of perineuronal satellitoses (characteristic invasive struc-
tures frequently seen in human gliomas), the tumor cells
show lower levels of pAKT and pERK1/2 than the neurons
they surround or the adjacent reactive astrocytes (Figure 1,
e–g and k–m). Together, the evidence from immunohisto-
chemistry indicates that the activities of both the AKT and
RAS/MAPK pathways are substantially decreased in glioma
cells by constitutive PDGF stimulation.
PDGF Stimulation Only Transiently Activates AKT and
RAS/MAPK Pathways
Although the above data suggest the absence of acti-
vated AKT and RAS/MAPK pathways in our tumor model of
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oligodendroglioma, PDGF stimulation has been reported
to activate both pathways in a series of cell culture sys-
tems [18–20]. Of note, one unique feature of our system
is the duration and fashion of PDGF stimulation. During
PDGF-induced gliomagenesis, PDGF functions chronically,
rather than transiently, through its receptors. Thus, the tem-
poral differencebetween theexperimental systemsmaysome-
how account for the paradox.
We investigated this possibility by establishing a culture
system in which PDGF-responding cells are under prolonged
PDGF stimulation. Prolonged stimulation of NIH3T3 cells
with recombinant PDGF/BB peptides resulted in transient
Figure 1. Absence of activated Akt and Ras/ERK pathways in PDGF-induced oligodendrogliomas. (a and c) Immunostaining of Akt, Ras-induced GBM with
specific anti-pAkt (Ser473), and anti –pERK1/2 (Thr202/Tyr204) antibody respectively. (b and d) Immunostaining of PDGF-induced oligodendroglioma with specific
anti-pAkt and anti –pERK1/2 antibody, respectively. All micrographs were taken at 100 magnification. (e and f) Immunostaining of invading areas of PDGF-
induced oligodendroglioma with specific anti-pAkt antibody. Perineuronal satellitoses are clearly illustrated. The neurons contain higher pAkt levels relative to the
surrounding tumor cells. Original magnification, 100 and 200, respectively. (g) Immunostaining of normal brain areas in the same PDGF-induced
oligodendroglioma sections with specific anti-pAkt antibody. Both cytoplasmic and nuclear staining are seen in neurons. (h and i) Immunostaining of invading areas
of PDGF-induced oligodendroglioma with anti-NeuN antibody. NeuN specifically stains neurons’ nuclei, illustrating perineuronal satellitoses. Original magnification,
100 and 1000, respectively. (j) PCNA stains the tumor cells, but not the neurons. PCNA, proliferating cell nuclear antigen. Original magnification, 600. (k and l)
Immunostaining of invading areas of PDGF-induced oligodendroglioma with specific anti –pERK1/2 antibody. Neurons contain higher pERK1/2 levels compared
with the surrounding tumor cells. Original magnification, 400 and 600, respectively. (m) Reactive astrocytes, indicated by the purple arrows, are stained with
pERK1/2, not the neighboring neoplastic cells. Original magnification, 600. In all micrographs, the red arrows indicate neurons and the yellow arrows indicate
surrounding tumor cells.
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elevation levels of pAKT and pERK1/2 as measured by
Western blot analysis. This activation occurred within
minutes and diminished gradually thereafter (Figure 2A).
Following the loss of phosphorylation of Akt and ERK1/2,
a separate group of events occurred in a delayed and
sustained fashion, including accumulation of PCNA and
p21/CIP1 protein (Figure 2A). Proliferating cell nuclear anti-
gen (PCNA) is essential for DNA replication [21,22], and
its increased level reflects PDGF’s mitogenic effect. p21/
CIP1, an inhibitor of cyclin-dependent kinases (CDKIs), has
been implicated in additional functions including facilitating
the assembly between CDK4 and cyclin D1 [23,24] and
antagonizing radiation– induced apoptosis [25–27]. A simi-
lar, but less impressive, pattern of dynamic changes in
sinaling pathway activity was also observed in cultured
primary mouse astrocytes with prolonged PDGF stimulation
(Figure 2B). This less potent effect seen in the primary
astrocytes may be, in part, due to an increased heteroge-
neity, more quiescent cell cycle status, and lower PDGFR
expression level of these primary cells compared with im-
mortalized NIH3T3 cells.
The above data indicate that PDGF stimulation elicits at
least two temporally independent signaling patterns: early
and delayed. Lack of synchrony between these two suggests
dissociation between the PDGF-induced mitogenic effect
and activation of the AKT and RAS/MAPK pathways. Fur-
thermore, the sustainable nature of the delayed events
implies that they could potentially participate in constitutive
PDGF stimulation and PDGF-induced gliomagenesis. Thus,
the key question is whether chronic autocrine PDGF signal-
ing resembles early or delayed signaling patterns.
Suppression of AKT and ERK1/2 Activity by Chronic
PDGF Stimulation in Cultured Glial Cells
We determined whether the delayed effects of PDGF
signaling are similar to chronic PDGF overexpression and,
Figure 2. PDGF stimulation causes a transient activation of Akt and Ras/MAPK pathways. (A) NIH3T3 cells were cultured in 10% FBS, and stimulated with
recombinant human PDGF/BB peptides at 20 ng/ml concentration. The cells were harvested at different time points from 0 minutes to 24 hours. The levels of pAkt,
pERK1/2, and pP38MAPK increased within minutes after stimulation and reached their maximum at 20 minutes. Their levels decreased rapidly thereafter and
returned to, or even slightly below, the baseline after 24 hours. In contrast, the levels of PCNA and p21/CIP1 started increasing after 2 hours and were sustained
until 24 hours. tAkt, total level of Akt; tERK1/2, total level of ERK1/2; PCNA, proliferating cell nuclear antigen; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase. (B) Primary brain cultures were prepared from newborn Gtv-a transgenic mice and infected with RCAS-Puro virus in vitro. After puromycin
selection, pure primary astrocytes were stimulated with 20 ng/ml recombinant human PDGF/BB peptides. (C) The PDGF-infected astrocytes were treated with
1 M PTK787 for 96 hours. The levels of both PCNA and p21/CIP1 decreased. (D) The expression of p21/CIP1 was elevated in the PDGF/HA– induced
oligodendrogliomas. N, normal brains; T, tumors.
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by extension, to gliomas driven by chronic autocrine loop.
We examined the signal transduction profiles of PDGF-over-
expressing glial cells by Western blot analyses. Primary
astrocytes expressing tv-a from the GFAP promoter (Gtv-a)
were prepared and infected with RCAS viruses encoding
the PDGF/B gene as described previously. The forced PDGF
expression and autocrine loop stimulation in these GFAP-
expressing astrocytes were selected for progenitor-like
cells manifesting elongated and bipolar morphology, rapid
proliferation rate, and characteristic gene expression pat-
tern. This effect was seen for both RCAS-PB, which encodes
PDGF-B, and RCAS-PBIG, which encodes PDGF-B fol-
lowed by IRES GFP [15].
Western blot analyses demonstrated that these Gtv-a
astrocytes infected with either RCAS-PBIG or RCAS-PB
viruses had decreased levels of pAKT (Ser473) and of the
three RAS/MAPK pathways, including pERK1/2 (Thr202/
Tyr204), pJNK (Thr183/Tyr185), and pP38MAPK (Thr180/
Tyr182) [28,29], relative to the cells infected with RCAS-lacZ
viruses (Figure 3A). By contrast, the phosphorylated form
of pPKCa/bII (Thr638/641) as well as pSTAT3 (Tyr705)
appeared not to correlate with PDGF signaling, implying
specific suppression of AKT and ERK1/2 activity by consti-
tutive PDGF stimulation. Nevertheless, it is formally possible
that this outcome may be caused by selection for a subset
of cells with relatively low AKT and MAPK activities during
extended culture. To test this possibility, we blocked the
PDGF signaling of these PDGF-overexpressing cells with
1 mM PTK787, a small molecule that inhibits the tyrosine
kinase activity of PDGFR [30]. We found that PTK787
Figure 3. Suppression of both AKT and RAS/MAPK pathways in RCAS-PDGF– infected astrocytes. (A) Primary Gtv-a–derived astrocytes were infected with
RCAS-lacZ, RCAS-PBIG, and RCAS-PB, respectively, with each group in duplicates. The four lines of PDGF-infected astrocytes demonstrated substantially
enhanced proliferation rate and progenitor-like morphology. Compared with the lacZ-infected cells, these PDGF-infected astrocytes showed substantial decreases
in pERK1/2, pJNK, and pP38MAPK levels, and a modest decrease in pAkt level. In contrast, there are no significant changes in pPKCa/II and pSTAT3 levels. (B)
The PBIG-infected astrocyte B line was treated with the PDGFR inhibitor, PTK787, at 1 M concentration for 7 days in duplicates. These cells demonstrated a
substantially decreased proliferation rate and morphologic reversion. PTK787 treatment induced significant increases in pERK1/2, pJNK, and pP39MAPK levels,
as well as a modest increase in pAKT level. In contrast, both pPKCa/II and pSTAT3 levels remained the same after PTK787 treatment. (C) The PDGF-infected
astrocytes were treated with PTK787 at 1 M for 1 and 24 hours. PDGFRa and PDGFR were precipitated, and the phosphorylation of receptors was detected
using antiphosphotyrosine antibody. Compared with the untreated cells, the PTK787 treatment inhibited the autophosphorylation of both receptor isoforms.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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under this condition reversed the suppression of both AKT
and ERK1/2 phosphorylation (Figure 3B), in addition to
the inhibition of autophosphorylation for both PDGFR iso-
forms (Figure 3C). We verified the effect of chronic PDGF
stimulation on the Ras pathway by analyzing Ras activity
directly using a Ras–Raf pull-down assay. This experiment
demonstrated the inhibitory effect of autocrine PDGF sig-
naling on Ras activity, and the reversal of this effect by
treatment of the cells with the PDGFR inhibitor, PTK787
(Figure 4). Taken together, these data suggest a causal role
for constitutive PDGF stimulation in the suppression of the
AKT and RAS/MAPK signaling pathways.
Consistent with the in vitro findings, the neoplastic cells
of PDGF-induced oligodendrogliomas displayed significantly
increased PCNA expression compared with adjacent non-
neoplastic cells, as demonstrated by immunohistochemistry
(Figure 1j ). Western blot analysis of tumor-bearing brains
from mice infected with RCAS-encoding PDGF/B gene dem-
onstrated elevated levels of p21/CIP1 compared with normal
brains (Figure 2D).
Sustained Activation of AKT and RAS Pathways
Interferes with PDGF Signaling
Our data support the notion that sustained AKT and
ERK1/2 activity represents a different signaling pattern than
a PDGF autocrine loop. It is unclear as to what effect forced
activation of these pathways would have on constitutive
PDGF signaling in vitro or in vivo. This is of particular in-
terest in light of the acquisition of AKT activity as gliomas
progress from grade 3 to grade 4 tumors in humans. There-
fore, we secondarily infected cultured PDGF-overexpressing
glial progenitor cells with RCAS viruses encoding a consti-
tutively active Akt or Kras (G12D) mutant. Relative to the
cells infected with RCAS-lacZ viruses, these RCAS-Akt–or
RCAS-Kras–infected cells showed a decreased expression
of the PDGF receptors, especially the b isoform, measured
Figure 4. Chronic PDGF stimulation decreases the levels of Kras activity.
Primary astrocytes were derived from Gtv-a transgenic mice and infected with
the indicated RCAS viruses. Cells were cultured in reduced serum (1% FBS)
overnight and levels of activated Kras were assayed directly by pull-down
with the Ras binding domain of Raf1. Chronic PDGF stimulation inhibits Kras
activity, whereas PDGFR blockade with 1 M PTK787 partially relieves this
inhibition.
Figure 5. Sustained activation of Akt and ERK pathways affects PDGF signaling. (A) PDGF-overexpressing glial progenitor cells were infected with RCAS-lacZ,
RCAS-Akt, and RCAS-Kras viruses, respectively, in duplicate. The expression of Akt was detected with anti-HA antibody. The expression of Kras was indicated by
both elevated Kras and pERK1/2 levels. (B) The PDGF-infected glial progenitor cells were reinfected with RCAS-lacZ and RCAS-Akt viruses, respectively. With
and without PTK787 treatment (1 M), these cells were stained with anti-GFAP antibody and visualized with fluorescence microscopy. The number of GFAP+ cells
relative to the total number of cells in a single vision field was counted and the values represent mean ± SE of data from four different fields in each experimental
group. All experiments were repeated at least twice. The percentage of GFAP+ cells in the lacZ-infected, PTK787-untreated group was 0.63 ± 0.09%; 1.45 ± 0.18%
in the lacZ-infected, PTK787-treated group; 1.75 ± 0.25% in the Akt-infected, PTK787-untreated group; and 6.95 ± 0.53% in the Akt-infected, PTK787-treated
group ( P values, Student’s t test). (C) The successful infection of Akt viruses in those PDGF-overexpressing progenitor cells was demonstrated by the expression
of HA tag.
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by Western blot analysis. This suppression was correlated
with the respective elevation of Akt and pERK1/2 phos-
phorylation (Figure 5A). These data suggest that sustained
activation of Akt or RAS pathways may, to some extent,
counteract PDGF signaling by this mechanism.
Further evidence of the counteractive effects of these
two signaling motifs is seen by the induction of astrocytic
differentiation by Akt activity in PDGF-driven cells. PDGF
signaling is known to promote the proliferation and to block
the differentiation of glial progenitor cells [15,31,32]. Con-
sistent with this notion, blockade of PDGF signaling by
PTK787 treatment caused an induction of astroglial differ-
entiation in PDGF-overexpressing progenitor cells (Ntv-a
cells) in vitro, as demonstrated by a modest increase in the
number of cells expressing astroglial marker GFAP com-
pared with the untreated cells (Figure 5B). Similarly, infection
of those PDGF-overexpressing progenitor cells with RCAS-
Akt viruses led to an increase in the number of GFAP-
expressing cells compared with the control cells infected
with RCAS-lacZ viruses (Figure 5B). Successful infection
with RCAS-Akt was confirmed by Western blotting for the
HA tag on viral Akt (Figure 5C). The combination of infec-
tion with RCAS-Akt virus and administration of PTK787
gave rise to a more than 10-fold increase in GFAP expres-
sion (Figure 5B). These data support counteracting effects
of activated Akt pathway and constitutive PDGF signaling
on astroglial differentiation. These observations parallel our
previous observation that Akt activity converts CNS non-
astrocytic spindle cell tumors induced by Ras in an INK4a-
Arf/ background to an astrocytic GBM morphology [33].
Taken together, these experiments indicate that elevated Akt
activity can shift nonastrocytic glial cells toward astrocytic
differentiation. Furthermore, not only is sustained activation
of Akt and Ras/MAPK pathways not part of constitutive
PDGF signaling, but that sustained activation of either path-
way interferes with constitutive PDGF signaling.
Sustained Activation of AKT Pathway Converts
PDGF-Induced Oligodendrogliomas into Astrocytomas
In Vivo
Infection with PDGF-encoding viruses alone generated
tumors in Ntv-a mice that are pure oligodendrogliomas in
character. To investigate whether sustained activation of Akt
pathway will influence PDGF-induced gliomagenesis in vivo,
we infected a total of 32 newborn Ntv-a transgenic mice
(neural progenitors) with a mixture of two viruses: RCAS-Akt
and RCAS-PDGF. Infection of Ntv-a mice with the RCAS-
Akt virus alone does not induce gliomas [12], whereas in-
fection with RCAS-PDGF alone produces gliomas of nearly
homogenous oligodendroglioma character [15]. Approxi-
mately 45% of the tumors arising from mice doubly infected
with RCAS-PDGF and RCAS-Akt are gliomas of mixed his-
tology, in which both oligodendroglial and astroglial com-
ponents are present (Figure 6, A and B). The expression of
virally encoded constitutively active Akt, as indicated by
staining for the HA epitope tag, localizes to the astroglial
tumor compartments of these mixed gliomas (Figure 6, C
and D). These regions are characterized by cells with abun-
dant eosinophilic cytoplasm and GFAP immunoreactivity
(Figure 6, E and F), and indicate that these portions of the
tumors arose from cells that were infected with both viruses.
The absence of HA staining in the adjacent oligodendroglial
tumor compartments indicates an origin from cells infected
by the PDGF vector alone. This is reinforced by immunos-
taining for Olig2, a marker of oligodendrocytes, which is
present in the oligodendroglial compartment but absent in
the astroglial tumor areas (Figure 6,G andH ). Therefore, the
presence of activated Akt pathway appears to convert the
PDGF-induced gliomas from an oligodendroglial cell histol-
ogy into an astroglial cell histology. These data support the
observation of low Akt pathway activity in PDGF-induced
oligodendrogliomas. In addition, the data suggest potential
transition between these two distinct glioma histologies,
based on two signaling motifs, both of which can be causal
for glioma formation.
Discussion
We have recapitulated two major types of human gliomas
in mice by constitutively activating particular signal trans-
duction pathways of nestin-expressing cells in vivo. The
combined activation of both Akt and Ras pathways induced
glioblastoma, the most malignant astroglial tumor, from
glial progenitors [12]. The constitutive activation of PDGF
signaling in the same cell population gives rise to oligo-
dendroglioma, a nonastroglial tumor. Glioblastoma and oli-
godendroglioma are two histopathologically and clinically
distinct groups of CNS neoplasms. Given the same apparent
cell of origin and genetic background, the distinct tumor
phenotypes likely reflect the differences in underlying sig-
naling characteristics.
The immunohistochemical staining in tumors supports
cell culture data, indicating that chronic autocrine PDGF
stimulation does not elevate the activity of either the Akt
or Ras/MAPK pathways. Our data are consistent with the
observation made in human glioma samples where oligo-
dendroglioma specimens have lower pAkt and pERK1/2
levels relative to the astrocytic GBMs [12,34]. It is possible
that although the levels of pAkt and pERK1/2 are low in the
PDGF-induced gliomas, the activity of these pathways may
still be critical to the progression of the tumor. Therapeutic
trials of murine PDGF-induced oligodendrogliomas with in-
hibitors of mTOR have shown that although mTOR activity
is low in these tumors, it is required for their proliferation [35].
In vivo, forced activation of the Akt pathway converts
PDGF-induced oligodendrogliomas into astrocytomas, con-
sistent with the absence of an activated Akt pathway in the
PDGF-driven oligodendrogliomas. The silencing of the Akt
pathway by chronic PDGF signaling could contribute to the
resultant oligodendroglioma phenotypes in this way. These
data suggest AKT activity levels as one possible mechanism
for transition between these two distinct types of gliomas
in humans.
Most thoughts on the issue of cell lineage in tumors are
derived from normal development, where the transition be-
tween cell types is unidirectional toward differentiation and
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the phenotype of the cells is governed by the characteristics
of the cell of origin. However, we demonstrate here that the
signaling abnormalities found in gliomas can change the
appearance of cells from one ‘‘lineage’’ to another. These
data suggest that regionally variable signaling characteristics
within tumors may provide one mechanism for the develop-
ment of tumors composed of cells apparently derived from
multiple lineages. Our data do not disprove cancer stem cells
as the origin of gliomas, but provide additional explanations
for the observations commonly attributed to that concept. It is
likely that the phenotype of a given tumor cell is ultimately
achieved by a combination of its signaling pathways and
characteristics of the cell of origin.
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